Literature DB >> 34043424

Immune Cells and Immunotherapy for Cardiac Injury and Repair.

Joel G Rurik1, Haig Aghajanian1, Jonathan A Epstein1.   

Abstract

Cardiac injury remains a major cause of morbidity and mortality worldwide. Despite significant advances, a full understanding of why the heart fails to fully recover function after acute injury, and why progressive heart failure frequently ensues, remains elusive. No therapeutics, short of heart transplantation, have emerged to reliably halt or reverse the inexorable progression of heart failure in the majority of patients once it has become clinically evident. To date, most pharmacological interventions have focused on modifying hemodynamics (reducing afterload, controlling blood pressure and blood volume) or on modifying cardiac myocyte function. However, important contributions of the immune system to normal cardiac function and the response to injury have recently emerged as exciting areas of investigation. Therapeutic interventions aimed at harnessing the power of immune cells hold promise for new treatment avenues for cardiac disease. Here, we review the immune response to heart injury, its contribution to cardiac fibrosis, and the potential of immune modifying therapies to affect cardiac repair.

Entities:  

Keywords:  fibrosis; heart disease; immunology; immunotherapy

Mesh:

Substances:

Year:  2021        PMID: 34043424      PMCID: PMC8171813          DOI: 10.1161/CIRCRESAHA.121.318005

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   23.213


  192 in total

1.  CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload.

Authors:  Fanny Laroumanie; Victorine Douin-Echinard; Joffrey Pozzo; Olivier Lairez; Florence Tortosa; Claire Vinel; Christine Delage; Denis Calise; Marianne Dutaur; Angelo Parini; Nathalie Pizzinat
Journal:  Circulation       Date:  2014-03-21       Impact factor: 29.690

2.  Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis.

Authors:  Benjamin Ng; Jinrui Dong; Giuseppe D'Agostino; Sivakumar Viswanathan; Anissa A Widjaja; Wei-Wen Lim; Nicole S J Ko; Jessie Tan; Sonia P Chothani; Benjamin Huang; Chen Xie; Chee Jian Pua; Ann-Marie Chacko; Nuno Guimarães-Camboa; Sylvia M Evans; Adam J Byrne; Toby M Maher; Jiurong Liang; Dianhua Jiang; Paul W Noble; Sebastian Schafer; Stuart A Cook
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

3.  Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

Authors:  T C Thomas; S A Rollins; R P Rother; M A Giannoni; S L Hartman; E A Elliott; S H Nye; L A Matis; S P Squinto; M J Evans
Journal:  Mol Immunol       Date:  1996-12       Impact factor: 4.407

4.  Receptor-associated Mad homologues synergize as effectors of the TGF-beta response.

Authors:  Y Zhang; X Feng; R We; R Derynck
Journal:  Nature       Date:  1996-09-12       Impact factor: 49.962

5.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

6.  Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease.

Authors:  B Villari; S E Campbell; O M Hess; G Mall; G Vassalli; K T Weber; H P Krayenbuehl
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

7.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

Review 8.  Molecular mechanisms of myocardial remodeling.

Authors:  B Swynghedauw
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

9.  Tissue-resident macrophages regulate lymphatic vessel growth and patterning in the developing heart.

Authors:  Thomas J Cahill; Xin Sun; Christophe Ravaud; Cristina Villa Del Campo; Konstantinos Klaourakis; Irina-Elena Lupu; Allegra M Lord; Cathy Browne; Sten Eirik W Jacobsen; David R Greaves; David G Jackson; Sally A Cowley; William James; Robin P Choudhury; Joaquim Miguel Vieira; Paul R Riley
Journal:  Development       Date:  2021-02-03       Impact factor: 6.868

Review 10.  Targeting senescent cells to attenuate cardiovascular disease progression.

Authors:  Ping Song; Qiang Zhao; Ming-Hui Zou
Journal:  Ageing Res Rev       Date:  2020-04-13       Impact factor: 10.895

View more
  16 in total

1.  Bone marrow-derived naïve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin.

Authors:  Yue Xu; Kai Jiang; Feng Chen; Jie Qian; Dandan Wang; Yizhang Wu; Chunjiang Zhou; Yong Yu; Kun Chen; John Hwa; Bing Yang; Haiyun Wang; Yaozu Xiang
Journal:  Basic Res Cardiol       Date:  2022-09-28       Impact factor: 12.416

Review 2.  The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism.

Authors:  Yukang Mao; Kun Zhao; Peng Li; Yanhui Sheng
Journal:  Mol Cell Biochem       Date:  2022-10-10       Impact factor: 3.842

3.  Nexinhib20 Inhibits Neutrophil Adhesion and β2 Integrin Activation by Antagonizing Rac-1-Guanosine 5'-Triphosphate Interaction.

Authors:  Wei Liu; Chunxia G Cronin; Ziming Cao; Chengliang Wang; Jianbin Ruan; Sunitha Pulikkot; Alexxus Hall; Hao Sun; Alex Groisman; Yunfeng Chen; Anthony T Vella; Liang Hu; Bruce T Liang; Zhichao Fan
Journal:  J Immunol       Date:  2022-09-07       Impact factor: 5.426

4.  Electroacupuncture pre-treatment alleviates sepsis-induced cardiac inflammation and dysfunction by inhibiting the calpain-2/STAT3 pathway.

Authors:  Xuqing Li; Li Wang; Xinwang Ying; Yujun Zheng; Qianqian Tan; Xiaolan Yu; Jiahong Gong; Ming Li; Xiaofeng Deng; Guanhu Yang; Shengcun Li; Songhe Jiang
Journal:  Front Physiol       Date:  2022-09-07       Impact factor: 4.755

5.  Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury.

Authors:  Xueyi Weng; Haipeng Tan; Zheyong Huang; Jing Chen; Ning Zhang; Qiaozi Wang; Qiyu Li; Jinfeng Gao; Dili Sun; Wusiman Yakufu; Zhengmin Wang; Weiyan Li; Guangrui Zhu; Zhiqing Pang; Yanan Song; Juying Qian; Junbo Ge
Journal:  J Nanobiotechnology       Date:  2022-10-20       Impact factor: 9.429

Review 6.  Engineered cellular immunotherapies in cancer and beyond.

Authors:  Amanda V Finck; Tatiana Blanchard; Christopher P Roselle; Giulia Golinelli; Carl H June
Journal:  Nat Med       Date:  2022-04-19       Impact factor: 87.241

7.  Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System In Vivo to Treat Heart Disease.

Authors:  Joel G Rurik; Jonathan A Epstein
Journal:  DNA Cell Biol       Date:  2022-04-20       Impact factor: 3.550

8.  Construction and Bioinformatics Analysis of circRNA-miRNA-mRNA Network in Acute Myocardial Infarction.

Authors:  Jin Zhou; Shaolin He; Boyuan Wang; Wenling Yang; Yuqi Zheng; Shijiu Jiang; Dazhu Li; Jibin Lin
Journal:  Front Genet       Date:  2022-03-29       Impact factor: 4.599

Review 9.  Lymphatic Clearance of Immune Cells in Cardiovascular Disease.

Authors:  Christophe Ravaud; Nikita Ved; David G Jackson; Joaquim Miguel Vieira; Paul R Riley
Journal:  Cells       Date:  2021-09-29       Impact factor: 7.666

Review 10.  Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases.

Authors:  Ting-Wei Kao; Chin-Chou Huang
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.